HLA-DRB1 and myeloid sarcoma: With regards to genetic variation IM and elevated antibody responses against EBV nuclear antigen 1 (EBNA1) have been found to synergize with the MHC class II molecule HLA-DRB1*1501 to increase risk for the development of MS (5).